[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Oxaliplatin.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oxaliplatin.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Oxaliplatin.]
[L04AA27, fingolimod, Oxaliplatin may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Oxaliplatin.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Oxaliplatin.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Oxaliplatin.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Oxaliplatin.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Oxaliplatin.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Oxaliplatin.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Oxaliplatin.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Oxaliplatin.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Oxaliplatin.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Oxaliplatin.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Thalidomide.]
[A11DA01, thiamine, The serum concentration of Oxaliplatin can be increased when it is combined with Thiamine.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Oxaliplatin.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Oxaliplatin.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Oxaliplatin.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Oxaliplatin.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Oxaliplatin.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxaliplatin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Triamcinolone.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Oxaliplatin.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Oxaliplatin.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Oxaliplatin.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Oxaliplatin.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Oxaliplatin.]
[J01EA01, trimethoprim, The serum concentration of Oxaliplatin can be increased when it is combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Oxaliplatin.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Oxaliplatin.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Oxaliplatin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belimumab.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Vandetanib.]
[A10BH05, linagliptin, The serum concentration of Oxaliplatin can be increased when it is combined with Linagliptin.]
[J05AG05, rilpivirine, Rilpivirine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Oxaliplatin.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belatacept.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Oxaliplatin.]
[B01AF01, rivaroxaban, The risk or severity of bleeding can be increased when Rivaroxaban is combined with Oxaliplatin.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Oxaliplatin.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Oxaliplatin.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Oxaliplatin.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Oxaliplatin.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Warfarin is combined with Oxaliplatin.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Oxaliplatin.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The serum concentration of Oxaliplatin can be increased when it is combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Oxaliplatin.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxaliplatin.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ziprasidone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oxaliplatin.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Oxaliplatin.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ruxolitinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Oxaliplatin.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Oxaliplatin.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Oxaliplatin.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Oxaliplatin.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Atropine.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Oxaliplatin.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Oxaliplatin.]
[G04BE10, avanafil, Avanafil may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Oxaliplatin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oxaliplatin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Oxaliplatin.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Carfilzomib.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Oxaliplatin.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Aldosterone.]
[L01EX05, regorafenib, Regorafenib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bendamustine.]
[L04AA29, tofacitinib, Oxaliplatin may increase the immunosuppressive activities of Tofacitinib.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Oxaliplatin.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Oxaliplatin.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Oxaliplatin.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Oxaliplatin.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pomalidomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxaliplatin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Benzocaine.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Oxaliplatin.]
[L01EC02, dabrafenib, The serum concentration of Oxaliplatin can be increased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Benzyl alcohol.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[J05AJ03, dolutegravir, The serum concentration of Oxaliplatin can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Bepridil.]
[L03AA14, lipegfilgrastim, Oxaliplatin may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ibrutinib.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Oxaliplatin.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Oxaliplatin.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ceritinib.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Oxaliplatin.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Oxaliplatin.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Oxaliplatin.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idelalisib.]
[N07XX08, tafamidis, The serum concentration of Oxaliplatin can be increased when it is combined with Tafamidis.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Oxaliplatin.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Peginterferon beta-1a.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Eliglustat.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pirfenidone.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Blinatumomab.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Oxaliplatin.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Oxaliplatin.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Oxaliplatin.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Oxaliplatin can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Panobinostat.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Oxaliplatin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Oxaliplatin.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Oxaliplatin.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Oxaliplatin.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mepolizumab.]
[J02AC05, isavuconazole, The serum concentration of Oxaliplatin can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, Osimertinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L01ED03, alectinib, Alectinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxaliplatin.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ixekizumab.]
[L01XX52, venetoclax, Venetoclax may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Oxaliplatin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Oxaliplatin.]
[N07BC01, buprenorphine, Buprenorphine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Oxaliplatin.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Oxaliplatin.]
[L01XK03, rucaparib, Rucaparib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Oxaliplatin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Brodalumab.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ribociclib.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Oxaliplatin.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Oxaliplatin.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Oxaliplatin.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Linezolid.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Oxaliplatin.]
[L01ED04, brigatinib, Brigatinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Oxaliplatin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Oxaliplatin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Capecitabine.]
[L01XX59, enasidenib, The serum concentration of Oxaliplatin can be increased when it is combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vorinostat.]
[L01EF03, abemaciclib, Abemaciclib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Oxaliplatin.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Oxaliplatin.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Oxaliplatin.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Oxaliplatin.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Oxaliplatin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Capsaicin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Oxaliplatin.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Oxaliplatin can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Carbamazepine.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Oxaliplatin.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[N03AX24, cannabidiol, Cannabidiol may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Baricitinib.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Encorafenib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Oxaliplatin.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ivosidenib.]
[P01BA07, tafenoquine, The serum concentration of Oxaliplatin can be increased when it is combined with Tafenoquine.]
[N03AX17, stiripentol, The excretion of Oxaliplatin can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, Dacomitinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Oxaliplatin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Chloroprocaine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Oxaliplatin.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Oxaliplatin.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amifampridine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ravulizumab.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Oxaliplatin.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Oxaliplatin.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Oxaliplatin.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Oxaliplatin.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Oxaliplatin can be increased when it is combined with Erdafitinib.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Oxaliplatin.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Risankizumab.]
[L02BB06, darolutamide, Darolutamide may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Oxaliplatin.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Upadacitinib.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Entrectinib.]
[N07XX11, pitolisant, Oxaliplatin may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Oxaliplatin.]
[N04CX01, istradefylline, Istradefylline may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Oxaliplatin.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Oxaliplatin.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trastuzumab emtansine.]
[N02CC08, lasmiditan, The serum concentration of Oxaliplatin can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Diroximel fumarate.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Oxaliplatin.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dexchlorpheniramine.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Teprotumumab.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Oxaliplatin.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ozanimod.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Oxaliplatin.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dronedarone.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Oxaliplatin.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Oxaliplatin.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Oxaliplatin.]
[L01EH03, tucatinib, The serum concentration of Oxaliplatin can be increased when it is combined with Tucatinib.]
[L01EX17, capmatinib, The serum concentration of Oxaliplatin can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluprednidene.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Oxaliplatin.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Oxaliplatin is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Stepronin.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Oxaliplatin.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Chloroquine.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Oxaliplatin.]
[R06AB04, chlorpheniramine, The serum concentration of Oxaliplatin can be increased when it is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Oxaliplatin.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Oxaliplatin.]
[N02BA03, choline salicylate, The serum concentration of Oxaliplatin can be increased when it is combined with Choline salicylate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Berotralstat.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fludarabine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Oxaliplatin.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Voclosporin.]
[L01EX21, tepotinib, Tepotinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[V03AF12, trilaciclib, The serum concentration of Oxaliplatin can be increased when it is combined with Trilaciclib.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Oxaliplatin.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Oxaliplatin.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Oxaliplatin.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Oxaliplatin.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Oxaliplatin.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Oxaliplatin.]
[A02BA01, cimetidine, The serum concentration of Oxaliplatin can be increased when it is combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Oxaliplatin can be increased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Oxaliplatin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Anifrolumab.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Clemastine.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Oxaliplatin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Oxaliplatin can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Clomipramine.]
[J02AC06, oteseconazole, The serum concentration of Oxaliplatin can be increased when it is combined with Oteseconazole.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Deucravacitinib.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Oxaliplatin is combined with Clozapine.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bimekizumab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Oxaliplatin.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Nelarabine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Oxaliplatin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Desloratadine.]
[J02AC02, itraconazole, Itraconazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Oxaliplatin.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Emedastine.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Oxaliplatin.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Oxaliplatin.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oxaliplatin.]
[N03AX09, lamotrigine, The serum concentration of Oxaliplatin can be increased when it is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Oxaliplatin.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Lomefloxacin.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Oxaliplatin.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Adenosine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Oxaliplatin.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Oxaliplatin.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Oxaliplatin.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cyclophosphamide.]
[S01XA18, cyclosporine, Oxaliplatin may increase the immunosuppressive activities of Cyclosporine.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Oxaliplatin.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Oxaliplatin.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Oxaliplatin.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Daunorubicin.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Oxaliplatin.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaliplatin.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Oxaliplatin.]
[N06AA01, desipramine, The serum concentration of Oxaliplatin can be increased when it is combined with Desipramine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Desoximetasone.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Oxaliplatin.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocinolone acetonide.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Oxaliplatin.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[B01AC04, clopidogrel, The serum concentration of Oxaliplatin can be increased when it is combined with Clopidogrel.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Cinchocaine.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Oxaliplatin.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Oxaliplatin.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ixabepilone.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Oxaliplatin.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Difluocortolone.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Oxaliplatin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Oxaliplatin.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Oxaliplatin.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Oxaliplatin.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Oxaliplatin.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Oxaliplatin.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Oxaliplatin.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dimenhydrinate.]
[G02AD02, dinoprostone, The serum concentration of Oxaliplatin can be increased when it is combined with Dinoprostone.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Oxaliplatin.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Oxaliplatin.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Cisapride.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sirolimus.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Oxaliplatin.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Oxaliplatin.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Oxaliplatin.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Oxaliplatin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Oxaliplatin.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Oxaliplatin.]
[C01EB18, ranolazine, The serum concentration of Oxaliplatin can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The serum concentration of Oxaliplatin can be increased when it is combined with Salmeterol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Domperidone.]
[C01CA04, dopamine, The serum concentration of Oxaliplatin can be increased when it is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Oxaliplatin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Oxaliplatin.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Doxorubicin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Oxaliplatin.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Oxaliplatin.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Oxaliplatin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sultopride.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Oxaliplatin.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Temozolomide.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Terodiline.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Oxaliplatin.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Toremifene.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Oxaliplatin.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trilostane.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxaliplatin.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Oxaliplatin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Oxaliplatin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Oxaliplatin.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Oxaliplatin.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Oxaliplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA01, epinephrine, The serum concentration of Oxaliplatin can be increased when it is combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Oxaliplatin.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Oxaliplatin.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Oxaliplatin.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Oxaliplatin.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Oxaliplatin.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Oxaliplatin.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[G03CA03, estradiol, The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Estramustine.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluticasone.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Oxaliplatin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Etoposide.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Oxaliplatin.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Oxaliplatin.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Oxaliplatin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Terfenadine.]
[N06AX12, bupropion, The excretion of Oxaliplatin can be decreased when combined with Bupropion.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Oxaliplatin.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxaliplatin.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Oxaliplatin.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Oxaliplatin.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Oxaliplatin.]
[A02BA03, famotidine, The serum concentration of Oxaliplatin can be increased when it is combined with Famotidine.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Oxaliplatin.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fendiline.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxaliplatin.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Oxaliplatin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Oxaliplatin.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Flecainide.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Oxaliplatin.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fludrocortisone.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Oxaliplatin.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Oxaliplatin.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxaliplatin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Flupentixol.]
[N05CD01, flurazepam, The serum concentration of Oxaliplatin can be increased when it is combined with Flurazepam.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fluspirilene.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Oxaliplatin.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Oxaliplatin.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Oxaliplatin.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dasatinib.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Oxaliplatin.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Oxaliplatin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dofetilide.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Oxaliplatin.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Oxaliplatin.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Oxaliplatin.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxaliplatin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Oxaliplatin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quetiapine.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Irinotecan.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Oxaliplatin.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Oxaliplatin.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Oxaliplatin.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Oxaliplatin.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Oxaliplatin.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Oxaliplatin.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Oxaliplatin.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Hydroxyzine.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Oxaliplatin.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ifosfamide.]
[N06AA02, imipramine, The serum concentration of Oxaliplatin can be increased when it is combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Oxaliplatin.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Topotecan.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Oxaliplatin.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaliplatin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Oxaliplatin.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Oxaliplatin.]
[S01XA28, varenicline, The serum concentration of Oxaliplatin can be increased when it is combined with Varenicline.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Articaine.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Oxaliplatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Anagrelide.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Oxaliplatin.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Oxaliplatin.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Oxaliplatin.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Tocilizumab.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Oxaliplatin.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Oxaliplatin.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Oxaliplatin.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Oxaliplatin.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Nalidixic acid.]
[N04BB01, amantadine, The serum concentration of Oxaliplatin can be increased when it is combined with Amantadine.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Oxaliplatin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Oxaliplatin.]
[C03DB01, amiloride, The serum concentration of Oxaliplatin can be increased when it is combined with Amiloride.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Lomustine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Loperamide.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Oxaliplatin.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mechlorethamine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Oxaliplatin.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Oxaliplatin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Oxaliplatin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Oxaliplatin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Melphalan.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Mepivacaine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Oxaliplatin.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pemetrexed.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Oxaliplatin.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Oxaliplatin.]
[V04CG05, methylene blue, The serum concentration of Oxaliplatin can be increased when it is combined with Methylene blue.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methylprednisolone.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxaliplatin.]
[C07AB02, metoprolol, The serum concentration of Oxaliplatin can be increased when it is combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Oxaliplatin.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Oxaliplatin.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Oxaliplatin.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxaliplatin.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Oxaliplatin.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Certolizumab pegol.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mycophenolic acid.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Oxaliplatin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Oxaliplatin.]
[N03AB05, fosphenytoin, Oxaliplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Oxaliplatin.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Oxaliplatin.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oxaliplatin.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Docetaxel.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levosimendan.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Oxaliplatin.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Iloperidone.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Oxaliplatin can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Oxaliplatin.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Oxaliplatin.]
[N07BA01, nicotine, The serum concentration of Oxaliplatin can be increased when it is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Oxaliplatin.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Oxaliplatin.]
[C01CA03, norepinephrine, The serum concentration of Oxaliplatin can be increased when it is combined with Norepinephrine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Oxaliplatin.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Oxaliplatin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Oxaliplatin.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Oxaliplatin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxaliplatin.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ofloxacin.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Rilonacept.]
[A02BC01, omeprazole, Omeprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Oxaliplatin.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Oxaliplatin.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Oxaliplatin.]
[C07AA02, oxprenolol, The serum concentration of Oxaliplatin can be increased when it is combined with Oxprenolol.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxaliplatin.]
[V04CH30, 4-aminohippuric acid, The serum concentration of Oxaliplatin can be increased when it is combined with Aminohippuric acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Oxaliplatin.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Paramethasone.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Oxaliplatin.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Penicillamine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pentostatin.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Oxaliplatin.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Oxaliplatin.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Oxaliplatin.]
[A10BA01, phenformin, The serum concentration of Oxaliplatin can be increased when it is combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Oxaliplatin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Oxaliplatin.]
[C04AX02, phenoxybenzamine, The serum concentration of Oxaliplatin can be increased when it is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Oxaliplatin.]
[N03AB02, phenytoin, Oxaliplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Pimozide.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Saquinavir.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Grepafloxacin.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Oxaliplatin.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Oxaliplatin.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Oxaliplatin.]
[J05AE03, ritonavir, Ritonavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Oxaliplatin.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Primaquine.]
[M04AB01, probenecid, The serum concentration of Oxaliplatin can be increased when it is combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Oxaliplatin.]
[G03DA04, progesterone, The serum concentration of Oxaliplatin can be increased when it is combined with Progesterone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Oxaliplatin.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Oxaliplatin.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Propafenone.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Oxaliplatin.]
[C07AA05, propranolol, The serum concentration of Oxaliplatin can be increased when it is combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Propylthiouracil.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Oxaliplatin.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Oxaliplatin.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Oxaliplatin.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Oxaliplatin.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Oxaliplatin.]
[P01AX05, quinacrine, The serum concentration of Oxaliplatin can be increased when it is combined with Quinacrine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Oxaliplatin can be increased when it is combined with Ranitidine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sulfasalazine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Oxaliplatin.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sotalol.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Oxaliplatin.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone butyrate.]
[H02CA04, levoketoconazole, The serum concentration of Oxaliplatin can be increased when it is combined with Levoketoconazole.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
